Advertisement
YOU ARE HERE: LAT HomeCollectionsHycor Biomedical Inc
IN THE NEWS

Hycor Biomedical Inc

FEATURED ARTICLES
BUSINESS
February 23, 2001
The Garden Grove manufacturer of medical diagnostic products posted fourth-quarter net income of $172,000, or 2 cents a share, down 15% from $203,000, or 3 cents a share, for the 1999 fourth quarter. Sales declined 13% to $4.1 million. Net income for the year rose to $981,000, or 12 cents a share, from $249,000, or 3 cents a share, for the prior year. Sales declined 7% to $17.1 million.
ARTICLES BY DATE
BUSINESS
April 25, 2001
The Garden Grove manufacturer of medical diagnostic products posted earnings of $148,000, or 2 cents a share, a 45% drop from $267,000, or 3 cents a share, reported for the same quarter last year. Revenue was down 7% to $4.3 million. The company said it is making "significant progress" in its nearly yearlong effort to find a partner or a merger candidate.
Advertisement
BUSINESS
October 11, 2000 | Dow Jones
Hycor Biomedical Inc., Garden Grove developer of medical diagnostic products, said Tuesday it has received U.S. Food and Drug Administration clearance to sell an autoimmune test designed to identify various forms of vasculitis, an inflammation of blood vessels. The Anti-MPO p-ANCA ELISA test is designed to indicate which form of vasculitis a patient has. It complements another test that the FDA previously approved, Hycor said.
BUSINESS
April 25, 1993
Hycor Biomedical Inc.: The Garden Grove maker of medical and diagnostic products incurred a first-quarter loss of $128,000, or 1 cent a share, contrasted with a profit of $797,000, or 9 cents a share, for the same period in 1992. Sales declined 14% to $5.9 million from $6.9 million.
BUSINESS
May 30, 1997 | (Dow Jones)
Hycor Biomedical Inc. said the Japanese government has approved marketing of the company's HY-TEC automated allergy testing product in Japan. Hycor Biomedical said it expects to start selling the product during the third quarter. The company, which develops and produces medical diagnostic products, received similar approval last week from the French government.
BUSINESS
July 16, 1998 | Dow Jones
Dr. Richard D. Hamill, Hycor Biomedical Inc.'s chairman, president and chief executive, will retire Friday, the Garden Grove maker of medical diagnostic products said. Hycor Biomedical said it named J. David Tholen president and chief executive and appointed director Samuel D. Anderson as chairman. Hamill will resign from the board but remain a consultant. Tholen had been president of International Murex Technologies Corp. since 1993.
BUSINESS
October 5, 1994
Hycor Biomedical Inc. said Tuesday it has completed its purchase of Medical Specialties International Inc. Hycor, an Irvine-based developer of medical diagnostic equipment, said it paid $2 million cash and 200,000 shares of its own stock for Medical Specialties, a South Plainfield, N.J., company that develops blood testing technology. Based on Tuesday's Nasdaq closing price of $4.625 a share for Hycor's stock, the total value of the transaction is about $2.9 million.
BUSINESS
January 25, 1999 | (John O'Dell)
Hycor Biomedical Inc. said it expects to report a fourth-quarter loss of about $5.5 million, or 77 cents a share, after taking a $5.3-million noncash write-down related to tax accounting changes and to reduction of the value of "goodwill" booked when the company acquired Medical Specialties International Inc. last year. Garden Grove-based Hycor said revenue for the fourth quarter should drop about 10% to $4.7 million from $5.2 million.
BUSINESS
December 15, 1999 | Dow Jones
Hycor Biomedical Inc., a Garden Grove maker of medical diagnostic products, said Tuesday that the U.S. Food and Drug Administration has cleared it to market another autoimmune test kit in the United States. Hycor said in a press release that the kit, called Rheumatoid Factor IgG ELISA, detects an antibody found in 80% of patients with rheumatoid arthritis.
BUSINESS
December 8, 1999 | (Dow Jones)
Hycor Biomedical Inc., a Garden Grove maker of medical diagnostic products, said Tuesday that it has received clearance from the U.S. Food and Drug Administration to market its newest autoimmune test kit in the United States. Hycor said the kit, called Anti-Cardiolipin IgM ELISA, detects the presence of antibodies associated with anti-phospholipid syndrome. These antibodies can cause clotting problems and low platelet counts in patients with autoimmune disease.
BUSINESS
July 22, 1992
Hycor Biomedical Inc., the Garden Grove manufacturer of medical and diagnostic products, said its profits more than tripled in the second quarter to $788,000, or 9 cents per share. That compares to net income of $219,000, or 4 cents a share, in the same period a year earlier. Sales in the latest three months rose 139% to $6.8 million, from $2.9 million. For the first half of the year, Hycor posted a $1.6-million profit, compared to $479,000 in 1991. Sales more than doubled, to $13.
Los Angeles Times Articles
|